内分泌科指南

订阅

MedSci主页 / 所有栏目 / 内分泌科指南

2018 ESE临床实践指南：成人肾上腺皮质癌的管理

2018-07-24 欧洲内分泌学会 Eur J Endocrinol. 2018 Jul 24.

成人肾上腺皮质癌

2018年7月，欧洲内分泌学会(ESE)发布了成人肾上腺皮质癌的管理指南，肾上腺皮质癌(ACC) 是一罕见的恶性肿瘤，本文的主要目的是为临床医生提供关于肾上腺皮质癌管理的实践指导建议。内容涉及ACC的诊断和疑似ACC，疑似局部ACC的手术治疗，病例检查，分期和预后因素，影像学检查和评估，辅助治疗，复发/晚期疾病恶管理，特殊情况的管理等。

中文标题：

2018 ESE临床实践指南：成人肾上腺皮质癌的管理

英文标题：

European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors.

发布机构：

欧洲内分泌学会

发布日期：

2018-07-24

简要介绍：

2018年7月，欧洲内分泌学会(ESE)发布了成人肾上腺皮质癌的管理指南，肾上腺皮质癌(ACC) 是一罕见的恶性肿瘤，本文的主要目的是为临床医生提供关于肾上腺皮质癌管理的实践指导建议。内容涉及ACC的诊断和疑似ACC，疑似局部ACC的手术治疗，病例检查，分期和预后因素，影像学检查和评估，辅助治疗，复发/晚期疾病恶管理，特殊情况的管理等。 

拓展指南：与肾上腺相关指南：

相关资料下载：
[AttachmentFileName(sort=100, fileName=2018 ESE临床实践指南：成人肾上腺皮质癌的管理)] GetToolGuiderByIdResponse(projectId=1, id=1ca891c0016215bd, title=2018 ESE临床实践指南：成人肾上腺皮质癌的管理, enTitle=European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors., guiderFrom=Eur J Endocrinol. 2018 Jul 24., authorId=null, author=, summary=2018年7月，欧洲内分泌学会(ESE)发布了成人肾上腺皮质癌的管理指南，肾上腺皮质癌(ACC) 是一罕见的恶性肿瘤，本文的主要目的是为临床医生提供关于肾上腺皮质癌管理的实践指导建议。内容涉及ACC的诊断和疑似ACC，疑似局部ACC的手术治疗，病例检查，分期和预后因素，影像学检查和评估，辅助治疗，复发/晚期疾病恶管理，特殊情况的管理等。 , cover=, journalId=null, articlesId=null, associationId=916, associationName=欧洲内分泌学会, associationIntro=欧洲内分泌学会（The European Society of Endocrinology，ESE）是欧洲内分泌学者学习和交流的圣地，旨在通过组织会议、提供培训课程和出版物等方式，促进内分泌领域内公益性研究、教育和临床实践等项目，提高公众意识，并对相关法规的完善起到监督作用。ESE工作主要集中于以下方面：①举办欧洲内分泌会议（European Congress of Endocrinology，ECE），为业内人士交流最新成果和经验提供平台；②提供指南和政策，为临床医生和研究人员提供技术支持，如病人资料、培训课程等；③通过&ldquo;职业生涯&rdquo;栏目组建特别兴趣小组、欧洲青年内分泌科学家委员会、ESE护理小组等以便于会员之间交流合作等。ESE网站还有相关新闻、奖金、教育与科研、出版物以及媒体中心等栏目。, copyright=0, guiderPublishedTime=Tue Jul 24 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>2018年7月，欧洲内分泌学会(ESE)发布了成人肾上腺皮质癌的管理指南，肾上腺皮质癌(ACC) 是一罕见的恶性肿瘤，本文的主要目的是为临床医生提供关于肾上腺皮质癌管理的实践指导建议。内容涉及ACC的诊断和疑似ACC，疑似局部ACC的手术治疗，病例检查，分期和预后因素，影像学检查和评估，辅助治疗，复发/晚期疾病恶管理，特殊情况的管理等。 </div> <div><br> </div>拓展指南：<strong>与<font color=red>肾上腺</font>相关指南：</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=42d191c001589a6f" title="NCCN临床实践指南：神经内分泌肿瘤和肾上腺瘤（2018.V2）" target=_blank>NCCN临床实践指南：神经内分泌肿瘤和肾上腺瘤（2018.V2）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=71f441c0015e890f" title="NCCN临床实践指南：神经内分泌肿瘤和肾上腺瘤（2018.V1）" target=_blank>NCCN临床实践指南：神经内分泌肿瘤和肾上腺瘤（2018.V1）</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=a51771c00150a09a" title="2017 SCCM/ESICM指南：危重患者危重症相关性肾上腺皮质功能不全的管理" target=_blank>2017 SCCM/ESICM指南：危重患者危重症相关性肾上腺皮质功能不全的管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=d5ef31c001a9325f" title="2017 KES临床指南：肾上腺偶发瘤的管理" target=_blank>2017 KES临床指南：肾上腺偶发瘤的管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=6923f1c0013803bd" title="α１肾上腺素能受体激动剂围术期应用专家共识（2017版）" target=_blank>α１肾上腺素能受体激动剂围术期应用专家共识（2017版）</a></li> 更多信息请点击：<a href="http://www.medsci.cn/guideline/list.do?q=%E8%82%BE%E4%B8%8A%E8%85%BA" target=_blank>有关肾上腺更多指南</a></ul>, tagList=[TagDto(tagId=78450, tagName=成人肾上腺皮质癌)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=2, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7612, appHits=212, showAppHits=0, pcHits=5471, showPcHits=3174, likes=168, shares=4, comments=13, approvalStatus=1, publishedTime=Sun Jul 29 00:00:11 CST 2018, publishedTimeString=2018-07-24, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun Jul 29 00:00:11 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 21:03:17 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018 ESE临床实践指南：成人肾上腺皮质癌的管理)])
2018 ESE临床实践指南：成人肾上腺皮质癌的管理
下载请点击：
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1214106, encodeId=52f112141061c, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecd78109752, createdName=ms7000001622695942, createdTime=Mon Apr 25 14:15:34 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972028, encodeId=bf989e202823, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef062285908, createdName=121d685bm30暂无昵称, createdTime=Tue Jun 08 23:59:30 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967213, encodeId=054c96e21311, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44b74390577, createdName=140a6d58m55暂无昵称, createdTime=Thu May 20 13:20:57 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950966, encodeId=41b395096618, content=希望医学事业不断前进, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d9b5473075, createdName=ms3000000600414697, createdTime=Thu Mar 25 11:34:02 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336715, encodeId=9a5e336e1577, content=指南，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Mon Aug 06 00:17:18 CST 2018, time=2018-08-06, status=1, ipAttribution=)]
    2022-04-25 ms7000001622695942

    很好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1214106, encodeId=52f112141061c, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecd78109752, createdName=ms7000001622695942, createdTime=Mon Apr 25 14:15:34 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972028, encodeId=bf989e202823, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef062285908, createdName=121d685bm30暂无昵称, createdTime=Tue Jun 08 23:59:30 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967213, encodeId=054c96e21311, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44b74390577, createdName=140a6d58m55暂无昵称, createdTime=Thu May 20 13:20:57 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950966, encodeId=41b395096618, content=希望医学事业不断前进, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d9b5473075, createdName=ms3000000600414697, createdTime=Thu Mar 25 11:34:02 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336715, encodeId=9a5e336e1577, content=指南，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Mon Aug 06 00:17:18 CST 2018, time=2018-08-06, status=1, ipAttribution=)]
    2021-06-08 121d685bm30暂无昵称

    很好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1214106, encodeId=52f112141061c, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecd78109752, createdName=ms7000001622695942, createdTime=Mon Apr 25 14:15:34 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972028, encodeId=bf989e202823, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef062285908, createdName=121d685bm30暂无昵称, createdTime=Tue Jun 08 23:59:30 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967213, encodeId=054c96e21311, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44b74390577, createdName=140a6d58m55暂无昵称, createdTime=Thu May 20 13:20:57 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950966, encodeId=41b395096618, content=希望医学事业不断前进, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d9b5473075, createdName=ms3000000600414697, createdTime=Thu Mar 25 11:34:02 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336715, encodeId=9a5e336e1577, content=指南，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Mon Aug 06 00:17:18 CST 2018, time=2018-08-06, status=1, ipAttribution=)]
    2021-05-20 140a6d58m55暂无昵称

    感谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1214106, encodeId=52f112141061c, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecd78109752, createdName=ms7000001622695942, createdTime=Mon Apr 25 14:15:34 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972028, encodeId=bf989e202823, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef062285908, createdName=121d685bm30暂无昵称, createdTime=Tue Jun 08 23:59:30 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967213, encodeId=054c96e21311, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44b74390577, createdName=140a6d58m55暂无昵称, createdTime=Thu May 20 13:20:57 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950966, encodeId=41b395096618, content=希望医学事业不断前进, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d9b5473075, createdName=ms3000000600414697, createdTime=Thu Mar 25 11:34:02 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336715, encodeId=9a5e336e1577, content=指南，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Mon Aug 06 00:17:18 CST 2018, time=2018-08-06, status=1, ipAttribution=)]
    2021-03-25 ms3000000600414697

    希望医学事业不断前进

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1214106, encodeId=52f112141061c, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ecd78109752, createdName=ms7000001622695942, createdTime=Mon Apr 25 14:15:34 CST 2022, time=2022-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=972028, encodeId=bf989e202823, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef062285908, createdName=121d685bm30暂无昵称, createdTime=Tue Jun 08 23:59:30 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=967213, encodeId=054c96e21311, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=44b74390577, createdName=140a6d58m55暂无昵称, createdTime=Thu May 20 13:20:57 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=950966, encodeId=41b395096618, content=希望医学事业不断前进, beContent=null, objectType=guider, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d9b5473075, createdName=ms3000000600414697, createdTime=Thu Mar 25 11:34:02 CST 2021, time=2021-03-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=336715, encodeId=9a5e336e1577, content=指南，学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Mon Aug 06 00:17:18 CST 2018, time=2018-08-06, status=1, ipAttribution=)]
    2018-08-06 liumin1987

    指南，学习了。

    0